Search

Search results

488 results found

Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.

Elmariah, Hany, Salman Otoukesh, Ambuj Kumar, Haris Ali, Shukaib Arslan, Geoffrey Shouse, Hoda Pourhassan, et al. 2024. “Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis After Haploidentical Peripheral Blood Stem Cell Transplantation With Post-Transplantation Cyclophosphamide.”. Transplantation and Cellular Therapy 30 (2): 229.e1-229.e11.

Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups.

Kumar, Ambuj, Heloisa P Soares, Lodovico Balducci, Benjamin Djulbegovic, and National Cancer Institute. 2007. “Treatment Tolerance and Efficacy in Geriatric Oncology: A Systematic Review of Phase III Randomized Trials Conducted by Five National Cancer Institute-Sponsored Cooperative Groups.”. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25 (10): 1272-6.